BAUM CHARLES M 4

What Happened

• Charles M. Baum, a director of Acrivon Therapeutics, received an equity award of 9,366 restricted stock units (RSUs) on May 18, 2026. The grant price reported was $0.00 (award/compensation), so no cash was paid by the insider for these units.
• These RSUs represent a contingent right to receive one share of Acrivon common stock per RSU and are scheduled to vest in full on May 18, 2027, subject to Baum’s continuous service through that date. The filing does not state an immediate cash value or shares owned after the grant.

Key Details

• Transaction date: 2026-05-18; Filing date: 2026-05-20 (Form 4 accession 0000905148-26-002557).
• Transaction type/code: Award/Grant (A); 9,366 RSUs granted at $0.00.
• Vesting / restriction: RSUs vest in full on May 18, 2027, contingent on continued service (see footnote).
• Shares owned after transaction: Not specified in the reported excerpt.
• Timeliness: Filing appears timely (filed two days after the transaction); no late filing flag noted.

Context

• RSU grants are typically compensation or retention tools rather than open-market purchases or sales; they do not necessarily signal a near-term trading view by the insider.
• Upon vesting, each RSU converts into one share (subject to any applicable tax withholding), at which point the insider could hold or sell the underlying shares per company policy and securities law.